ZT ZTS Zoetis Loading... : Bullish and Bearish Analyst Opinions

Zoetis is down 54% from its 2022 peak, trading at decade-low multiples, yet remains the clear leader in animal health. The market fears GLP-1 drugs will eliminate pet care spending, but this is overblown; pet healthcare demand is resilient. Buy Zoetis at depressed levels for a long-term compounder with a strong moat and a temporary fear-based discount. GLP-1 drugs could reduce pet obesity-related spending; new animal health competitors; regulatory changes.

ZTS trades at 13x P/E with consistent 9% EPS growth, a rare combo in a high-quality, defensive subsector. A 50% drawdown has compressed valuation to levels not seen in years, creating a margin of safety for mean reversion. Buy a dominant animal pharma franchise at a cheap multiple with steady growth – classic value play. Slowing pet adoption/post-pandemic demand normalization, generic competition, regulatory changes in veterinary drugs, or negative currency effects.

ZTS trades at 13x P/E while delivering 9% EPS growth, and management increased debt by 50% to fund buybacks. The combination of low valuation, positive EPS growth, and aggressive management buybacks (signaling intrinsic value > current price) creates a contrarian value opportunity. Buy ZTS as a value play on temporary pet sector headwinds, with management providing a strong signal through leveraged buybacks. Continued contraction in the pet segment; macro slowdown in animal health spending; rising debt service costs if rates stay high.